Vyne Therapeutics Inc
VYNE0.365USD
+0.012+3.49%
종가 08/04, 16:00（ET）시세는 15분 지연됩니다
5.83M시가총액
손실P/E TTM
자세한 내용은 Vyne Therapeutics Inc 회사
VYNE Therapeutics Inc. is a biopharmaceutical company. The Company is focused on developing differentiated therapies for the treatment of immuno-inflammatory conditions. Its product candidate is VYN201, a locally administered pan-BET inhibitor designed as a soft drug to address diseases involving multiple, diverse inflammatory cell signaling pathways while providing low systemic exposure. Its second program is VYN202, a BD2-selective oral small molecule bromodomain and extra-terminal (BET) inhibitor in preclinical development for the treatment of immuno-inflammatory indications. The Company has rights to research, develop and commercialize products containing BET inhibitor compounds for the treatment of any disease, disorder or condition in humans. Utilizing its InhiBET platform and through its preclinical and clinical activities, the Company is evaluating the impact that BET inhibitor compounds have on regulating pro-inflammatory cytokines.
회사 정보
종목 코드 VYNE
회사 이름Vyne Therapeutics Inc
상장일Jan 25, 2018
CEOMr. David Domzalski
직원 수13
유형Ordinary Share
회계 연도 종료Jan 25
주소685 Route 202/206 N., Suite 301
도시BRIDGEWATER
증권 거래소NASDAQ Capital Market Consolidated
국가United States of America
우편 번호08807
전화18007757936
웹사이트https://vynetherapeutics.com/
종목 코드 VYNE
상장일Jan 25, 2018
CEOMr. David Domzalski
회사 임원
이름
이름/직위
직위
주식 보유
변동
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.19K
-2.86%
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
51.47K
--
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
42.30K
-5.45%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Mr. Anthony Bruno
Mr. Anthony Bruno
Independent Director
Independent Director
--
--
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Ms. Sharon Barbari
Ms. Sharon Barbari
Independent Director
Independent Director
--
--
Dr. Christine Borowski, Ph.D.
Dr. Christine Borowski, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Domzalski
Mr. David Domzalski
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Ms. Elisabeth A. Sandoval Little
Ms. Elisabeth A. Sandoval Little
Independent Director
Independent Director
--
--
이름
이름/직위
직위
주식 보유
변동
Mr. Tyler Zeronda
Mr. Tyler Zeronda
Chief Financial Officer, Treasurer
Chief Financial Officer, Treasurer
116.19K
-2.86%
Mr. Patrick G. Lepore
Mr. Patrick G. Lepore
Lead Independent Director
Lead Independent Director
51.47K
--
Ms. Mutya Fonte Harsch, J.D.
Ms. Mutya Fonte Harsch, J.D.
Chief Legal Officer, General Counsel, Secretary
Chief Legal Officer, General Counsel, Secretary
42.30K
-5.45%
Mr. Steven L. Basta
Mr. Steven L. Basta
Independent Director
Independent Director
7.45K
--
Mr. Anthony Bruno
Mr. Anthony Bruno
Independent Director
Independent Director
--
--
Dr. Iain Stuart, Ph.D.
Dr. Iain Stuart, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
수익 분석
통화: USD마지막 업데이트: Sun, Jul 6
통화: USD마지막 업데이트: Sun, Jul 6
FY2024
FY2023
FY2022
FY2021
FY2020
사업별USD
이름
수익
비율
Royalty revenues
501.00K
0.00%
데이터 없음
사업별
지역별
사업별USD
이름
수익
비율
Royalty revenues
501.00K
0.00%
주식 보유 통계
마지막 업데이트: Sun, Jun 1
마지막 업데이트: Sun, Jun 1
주주
주주 유형
주주
주주
비율
Eventide Asset Management, LLC
8.37%
Access Industries, Inc.
6.70%
Citadel Advisors LLC
6.60%
Acorn Capital Advisors, LLC
4.72%
Delaware Street Capital, L.L.C.
4.18%
Other
69.43%
주주
주주
비율
Eventide Asset Management, LLC
8.37%
Access Industries, Inc.
6.70%
Citadel Advisors LLC
6.60%
Acorn Capital Advisors, LLC
4.72%
Delaware Street Capital, L.L.C.
4.18%
Other
69.43%
주주 유형
주주
비율
Hedge Fund
26.69%
Investment Advisor
17.90%
Corporation
6.70%
Individual Investor
2.22%
Private Equity
1.54%
Investment Advisor/Hedge Fund
1.05%
Research Firm
0.32%
Venture Capital
0.20%
Other
43.37%
기관 주식 보유
마지막 업데이트: Tue, Jul 1
마지막 업데이트: Tue, Jul 1
보고 기간
기관 수
보유 주식
비율
변동
2025Q2
83
9.44M
56.62%
-1.32M
2025Q1
81
9.36M
56.20%
-1.38M
2024Q4
92
9.37M
63.49%
-533.87K
2024Q3
88
8.98M
61.30%
-594.32K
2024Q2
89
9.65M
66.73%
+287.65K
2024Q1
92
9.64M
67.66%
+101.95K
2023Q4
101
10.22M
72.71%
+4.63M
2023Q3
117
471.27K
14.37%
-340.06K
2023Q2
135
501.83K
15.37%
-314.68K
2023Q1
168
461.83K
16.95%
-412.21K
더 보기
주주 활동
이름
보유 주식
비율
변동
Chg %
날짜
Eventide Asset Management, LLC
1.39M
8.37%
--
--
Mar 31, 2025
Access Industries, Inc.
1.12M
6.7%
--
--
Feb 14, 2025
Citadel Advisors LLC
1.10M
6.6%
-130.13K
-10.58%
Mar 31, 2025
Acorn Capital Advisors, LLC
785.94K
4.72%
+328.97K
+71.99%
Mar 31, 2025
Delaware Street Capital, L.L.C.
696.47K
4.18%
--
--
Sep 30, 2024
Dafna Capital Management, LLC
636.10K
3.82%
+636.10K
--
Mar 31, 2025
The Vanguard Group, Inc.
475.65K
2.85%
+521.00
+0.11%
Mar 31, 2025
Exome Asset Management LLC
462.80K
2.78%
+109.37K
+30.94%
Mar 31, 2025
Palo Alto Investors LP
445.43K
2.67%
--
--
Mar 31, 2025
Adage Capital Management, L.P.
344.13K
2.06%
+190.00K
+123.27%
Mar 31, 2025
더 보기
관련 ETF
마지막 업데이트: Sat, Aug 2
마지막 업데이트: Sat, Aug 2
이름
비율
iShares Micro-Cap ETF
0%
iShares Micro-Cap ETF
비율0%
주식 배당금
지난 5년 동안 총
0.00
USD의 배당금이 분배되었습니다.
날짜
배당금
기준일
지급일
배당락일
데이터 없음
주식 분할
날짜
유형
비율
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 12, 2021
Merger
4<1
Feb 12, 2021
Merger
4<1
날짜
유형
비율
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 10, 2023
Merger
18<1
Feb 12, 2021
Merger
4<1
Feb 12, 2021
Merger
4<1
Feb 12, 2021
Merger
4<1
Feb 12, 2021
Merger
4<1
